Updates are available Correction dated 2016-04-08

Click to view Correction: https://doi.org/10.1007/s11523-016-0433-x

Epidermal Growth Factor Receptor (EGFR) Pathway Biomarkers in the Randomized Phase III Trial of Erlotinib Versus Observation in Ovarian Cancer Patients with No Evidence of Disease Progression after First-Line Platinum-Based Chemotherapy

Crossref DOI link: https://doi.org/10.1007/s11523-015-0369-6

Published Online: 2015-05-26

Published Print: 2015-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark